Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03219450 · ClinicalTrials.gov registry record · Phase 1
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
A Phase 1 study of Lymphocytic Leukemia, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03219450: Recruiting Phase 1 study of Lymphocytic Leukemia, sponsored by Dana-Farber Cancer Institute.
NCT03219450 is a Phase 1 study of Lymphocytic Leukemia that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 15 participants, below the 25-participant average among 4 other Lymphocytic Leukemia trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03219450, a Phase 1 study of Lymphocytic Leukemia, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: * Personalized NeoAntigen Vaccine * Poly-ICLC * Cyclophosphamide * Pembrolizumab
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cyclophosphamide
- DRUG NeoVax
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-08-18 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03219450
The ClinicalTrials.gov registry entry for NCT03219450 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 25-participant average among 4 other Lymphocytic Leukemia trials with a reported enrollment target (40% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03219450 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03219450 about?
NCT03219450 is a clinical study titled "A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.". This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: * Personalized NeoAntigen Vaccine * Poly-ICLC * Cyclophosphamide * Pembrolizumab
What is the current status of trial NCT03219450?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-08-18. Estimated completion is 2028-03-31.
What conditions does trial NCT03219450 study?
This clinical trial studies the following conditions: Lymphocytic Leukemia.
What interventions are being tested in trial NCT03219450?
The interventions under investigation include: Pembrolizumab (DRUG), Cyclophosphamide (DRUG), NeoVax (DRUG).
Who is sponsoring clinical trial NCT03219450?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03219450 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
COMPLETED · Phase 1
-
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
COMPLETED · Phase 1
-
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
COMPLETED · Early Phase 1
-
Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab
COMPLETED · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.